Paper Details

  1. Home
  2. Paper Details

Evaluation of Galcanezumab for the Prevention of Episodic Migraine: The EVOLVE-1 Randomized Clinical Trial.

Author: AilaniJessica, CarterJeffrey N, ConleyRobert R, DodickDavid W, StaufferVirginia L, ZhangQi

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

Galcanezumab 120-mg and 240-mg monthly injections significantly reduced monthly migraine headache days compared with placebo. The incidence rate of adverse events was low, demonstrating the favorable tolerability profile of galcanezumab.
Paper Details　
Original Abstract of the Article :
IMPORTANCE: Migraine is a disabling neurological disease characterized by severe headache attacks. Treatment options reduce migraine frequency for many patients, but adverse effects lead to discontinuation in many patients. OBJECTIVE: To demonstrate that galcanezumab is superior to placebo in the p...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6143119/

データ提供：米国国立医学図書館（NLM）

Galcanezumab: A Novel Treatment Option for Episodic Migraine

Migraine, a debilitating neurological disorder, can significantly impact an individual's quality of life. This study evaluates the effectiveness of galcanezumab, a new monoclonal antibody, in preventing episodic migraine. The authors assess the efficacy and safety of galcanezumab in a large, randomized, placebo-controlled clinical trial.

The study demonstrates that galcanezumab effectively reduces the frequency and severity of migraine headaches, offering a significant improvement in quality of life for many patients. The drug showed a favorable tolerability profile, with a low incidence of adverse events. The study highlights the potential of galcanezumab as a valuable new treatment option for episodic migraine.

A New Weapon in the Fight Against Migraine

This research offers a promising new treatment option for migraine sufferers. The effectiveness and safety of galcanezumab provide a significant advancement in the management of this debilitating condition.

Finding Relief from Migraine

For those struggling with migraine, this study offers a glimmer of hope. The development of new treatments like galcanezumab provides a new avenue for finding relief from this debilitating condition, potentially improving the quality of life for millions of people.

Dr.Camel's Conclusion

Like a desert oasis providing a much-needed source of water, galcanezumab offers relief to those suffering from migraine. This study demonstrates its effectiveness and safety, potentially offering a new path towards a life less burdened by migraine.

Date :
  1. Date Completed 2019-09-26
  2. Date Revised 2022-04-09
Further Info :

Pubmed ID

29813147

DOI: Digital Object Identifier

PMC6143119

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.